Eur Rev Med Pharmacol Sci 2019; 23 (7): 2786-2793

DOI: 10.26355/eurrev_201904_17553

HCP5 promotes colon cancer development by activating AP1G1 via PI3K/AKT pathway

W.-K. Yun, Y.-M. Hu, C.-B. Zhao, D.-Y. Yu, J.-B. Tang

Department of Radiotherapy, Harbin Medical University Cancer Hospital, Harbin, China. jess_tong@163.com


OBJECTIVE: To explore whether HCP5 participates in the pathogenic progression of colon cancer (CC) and its underlying mechanism.
PATIENTS AND METHODS: HCP5 expression in CC tissues and cell lines was detected by quantitative Real Time-Polymerase Chain Reaction (qRT-PCR). The correlation between the HCP5 expression and tumor stage of CC patients was then analyzed. After CC cells were transfected with HCP5-siRNA, the proliferation and migration capacities were detected by cell counting kit-8 (CCK-8), colony formation and transwell assay, respectively. Cell cycle was examined by flow cytometry. Western blot was conducted to detect protein expressions of HCP5, AP1G1 and relative molecules in the PI3K/AKT pathway. Rescue experiments were performed by co-transfection of HCP5-siRNA and AP1G1-siRNA into CC cells, followed by cell function detection.
RESULTS: HCP5 was highly expressed, whereas AP1G1 was lowly expressed in CC tissues and cell lines. Besides, CC patients with stage III-IV presented higher expression of HCP5 than those with stage I-II. The knockdown of HCP5 in CC cells down-regulated proliferation and migration capacities, and arrested cell cycle in the G0/G1 phase, which was reversed by the AP1G1 knockdown. In addition, HCP5 knockdown up-regulated AP1G1 expression, whereas down-regulated the expression of relative proteins in the PI3K/AKT pathway.
CONCLUSIONS: HCP5 was significantly increased in CC and enhanced the proliferation and migration of CC cells by inhibiting the AP1G1 expression. HCP5 promoted CC development by activating the PI3K/AKT pathway.

Free PDF Download

To cite this article

W.-K. Yun, Y.-M. Hu, C.-B. Zhao, D.-Y. Yu, J.-B. Tang
HCP5 promotes colon cancer development by activating AP1G1 via PI3K/AKT pathway

Eur Rev Med Pharmacol Sci
Year: 2019
Vol. 23 - N. 7
Pages: 2786-2793
DOI: 10.26355/eurrev_201904_17553